[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 1,788
Citations 0
Correction
October 6, 2015

Omitted Financial Disclosures

JAMA. 2015;314(13):1404. doi:10.1001/jama.2015.11728

In the Viewpoint “Deciphering Cholesterol Treatment Guidelines: A Clinician’s Perspective” published in the March 10, 2015, issue of JAMA,1 and in the subsequent reply letter entitled “Clinician Understanding of Cholesterol Treatment Guidelines” published in the June 16, 2015, issue of JAMA,2 the author neglected to cite conflict of interest disclosures. Dr Ganda reports receiving research funding from Amarin Pharmaceuticals, consulting fees from Amgen and Sanofi, and speaker’s honoraria from Janssen and Merck. These articles were corrected online.

References
1.
Ganda  OP.  Deciphering cholesterol treatment guidelines: a clinician’s perspective. JAMA. 2015;313(10):1009-1010.
PubMedArticle
2.
Ganda  OP.  Clinician understanding of cholesterol treatment guidelines. JAMA. 2015;313(23):2381-2382.
PubMedArticle
×